Brain Effects of Escitalopram and Citalopram Using fMRI

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

27 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Escitalopram (Lexapro) and citalopram (Celexa) are similar selective serotonin reuptake inhibitors that alter blood flow to the amygdala and other brain structures involved in regulating mood. Escitalopram consists of S-citalopram while citalopram contains both S-citalopram and R-citalopram (racemic citalopram). There is evidence that R-citalopram may block the effects of S-citalopram. The hypothesis being tested is that because of the antagonist effect of R-citalopram, S-citalopram will have a greater effect on the mood circuit than racemic citalopram when equal doses of S-citalopram are administered. The study design consists of a two week medication period followed by blood oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) while viewing affective visual stimuli.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863

Major Depression

COMPLETED PHASE4

Brain Energy Metabolism in Individuals With Major Depressive Disorder Receiving Escitalopram

NCT00183677

Depression

COMPLETED PHASE4

Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

NCT00109044

Major Depressive Disorder

COMPLETED PHASE3

Specific Effects of Escitalopram on Neuroendocrine Response

NCT00150527

Healthy

COMPLETED

The Effects of Increased Central Serotonergic Activity on Information Processing

NCT00206934

Healthy Volunteers

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Antidepressant Activity in Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Escitalopram

One week of escitalopram at 10 mg followed by one week at 20 mg in healthy volunteers.

Group Type ACTIVE_COMPARATOR

Escitalopram

Intervention Type DRUG

One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.

Citalopram

One week of citalopram at 20 mg followed by one week at 40 mg in healthy volunteers.

Group Type ACTIVE_COMPARATOR

Citalopram

Intervention Type DRUG

One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.

Placebo

Two weeks of placebo in healthy volunteers.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Two weeks of placebo taken orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.

Intervention Type DRUG

Citalopram

One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.

Intervention Type DRUG

Placebo

Two weeks of placebo taken orally.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lexapro Celexa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male aged 21 to 50 years.
* Capable of providing informed consent.
* Has an established residence and phone.

Exclusion Criteria

* Meets DSM-IV criteria for an Axis I or II disorder.
* History of substance dependence or abuse within the past month.
* Use of NSAID's, beta blockers, calcium channel blockers, antidepressants, antipsychotic medications, lithium or other medication which in the opinion of the investigator would alter vascular responsivity.
* Regular use of sedative hypnotic or narcotic medication, or other medication that might affect the individual's perception of visual stimuli.
* History of cataracts or significant visual impairment.
* A medical condition, which in the opinion of the investigator is likely to affect the individual's perception of the visual stimuli or vascular response.
* Participation in a research protocol that included administration of medication within the past 3 months.
* Cigarette smoking.

Minimum Eligible Age

21 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes